Impact of Combination Antibiogram and Related Education on Inpatient Fluoroquinolone Prescribing Patterns for Patients With Health Care–Associated Pneumonia

Background: Previous studies have shown that development of a unit-specific combination antibiogram improves optimal selection of empiric therapy for Gram-negative infections, yet no published data exist regarding the role of the combination antibiogram as an antimicrobial stewardship program tool for disease-specific prescribing. Objective: To evaluate the utility of a combination antibiogram to guide antibiotic prescribing for patients with health care–associated pneumonia (HCAP). Methods: This was a retrospective preprovider and postprovider education intervention study aimed to evaluate fluoroquinolone (FQ) use in patients with HCAP. Data were collected retrospectively to evaluate antibiotic prescribing patterns and patient outcomes. Results: A total of 87 patients were eligible for study inclusion. The primary end point, FQ days of therapy (DOT) was decreased by 2.3 days (P < 0.001). The secondary end point included FQ DOT per 1000 patient-days in patients with discharge diagnosis-related group of pneumonia and was decreased by 83.5 days (P = 0.08); double coverage reduced by 13% postintervention (P = 0.22); mean days of double coverage decreased by 2.1 days (P < 0.001), and length of stay was shortened by 2.1 days (P = 0.22). Clinical success was achieved more often in the postintervention group (90% vs 98%, P = 0.18) when compared with the preintervention group. No difference was found in microbiological outcomes in the subset of microbiologically evaluable patients (P = 0.57). Conclusion: Facility-specific combination antibiograms may be used to inform antibiotic prescribing in HCAP patients.

[1]  C. Gentry,et al.  Outcomes of Health Care–Associated Pneumonia Empirically Treated with Guideline-Concordant Regimens Versus Community-Acquired Pneumonia Guideline–Concordant Regimens for Patients Admitted to Acute Care Wards from Home , 2013, The Annals of pharmacotherapy.

[2]  D. Chung,et al.  Community-acquired pneumonia requiring hospitalization among U . S . adults , 2016 .

[3]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[4]  Daniel J Sexton,et al.  Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.

[5]  L. Leibovici,et al.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. , 2004, BMJ.

[6]  Marin H Kollef,et al.  Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. , 2005, Chest.

[7]  L. Lanthier,et al.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  W. Scheld,et al.  Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors , 2003, Emerging infectious diseases.

[9]  S. Weber,et al.  Optimizing Empirical Antimicrobial Therapy for Infection due to Gram-Negative Pathogens in the Intensive Care Unit: Utility of a Combination Antibiogram , 2010, Infection Control &#x0026; Hospital Epidemiology.

[10]  T. V. Van Schooneveld,et al.  Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia , 2014, Antimicrobial Agents and Chemotherapy.

[11]  M. Niederman,et al.  A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  H. Saka,et al.  Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. , 2013, American journal of respiratory and critical care medicine.

[13]  M. Kollef,et al.  A comparison of culture-positive and culture-negative health-care-associated pneumonia. , 2010, Chest.

[14]  J. Quinn,et al.  Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. , 2003, JAMA.

[15]  Leonard Leibovici,et al.  β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[16]  M. Niederman,et al.  Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia , 2009, Current opinion in infectious diseases.

[17]  D. Gerding Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S. Ewig,et al.  Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Weiner,et al.  Identification of Optimal Combinations for Empirical Dual Antimicrobial Therapy of Pseudomonas aeruginosa Infection: Potential Role of a Combination Antibiogram , 2006, Infection Control &#x0026; Hospital Epidemiology.

[20]  M. Kollef,et al.  Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience , 2007, Antimicrobial Agents and Chemotherapy.

[21]  N. Boyd,et al.  Combination Antibiotic Therapy for Empiric and Definitive Treatment of Gram‐Negative Infections: Insights from the Society of Infectious Diseases Pharmacists , 2011, Pharmacotherapy.